New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:37 EDTPRGOPerrigo near-term outlook has improved, says RBC Capital
RBC Capital expects Perrigo to benefit from several positive catalysts, including lower buyside expectations, tailwinds for the company's consumer health business, and increased focus on its Tysabri SPMS opportunity. The firm keeps a $160 price target and Outperform rating on the shares.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
10:12 EDTPRGOHigh option volume stocks
Subscribe for More Information
December 17, 2014
13:32 EDTPRGOPerrigo jumps after analyst discusses potential takeover by Teva
Subscribe for More Information
09:26 EDTPRGOPerrigo would be good acquisition for Teva, says RBC Capital
RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use